JP2024502235A5 - - Google Patents
Info
- Publication number
- JP2024502235A5 JP2024502235A5 JP2023537297A JP2023537297A JP2024502235A5 JP 2024502235 A5 JP2024502235 A5 JP 2024502235A5 JP 2023537297 A JP2023537297 A JP 2023537297A JP 2023537297 A JP2023537297 A JP 2023537297A JP 2024502235 A5 JP2024502235 A5 JP 2024502235A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- seq
- mage
- amino acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129447P | 2020-12-22 | 2020-12-22 | |
| US63/129,447 | 2020-12-22 | ||
| PCT/US2021/064504 WO2022140321A2 (en) | 2020-12-22 | 2021-12-21 | Mage-b2-specific t-cell receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502235A JP2024502235A (ja) | 2024-01-18 |
| JP2024502235A5 true JP2024502235A5 (enExample) | 2024-12-27 |
Family
ID=79730149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537297A Pending JP2024502235A (ja) | 2020-12-22 | 2021-12-21 | Ｍａｇｅ－ｂ２特異的ｔ細胞受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240100162A1 (enExample) |
| EP (1) | EP4267173A2 (enExample) |
| JP (1) | JP2024502235A (enExample) |
| AU (1) | AU2021410689A1 (enExample) |
| CA (1) | CA3205810A1 (enExample) |
| MX (1) | MX2023007519A (enExample) |
| WO (1) | WO2022140321A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024137652A2 (en) * | 2022-12-20 | 2024-06-27 | Abata Therapeutics, Inc. | Cell therapies for type 1 diabetes |
| CN121358777A (zh) * | 2023-07-27 | 2026-01-16 | 伊玛提克斯生物技术有限公司 | 抗mageb2的抗原结合蛋白 |
| WO2025021979A1 (en) * | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| WO2026025031A1 (en) * | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010126766A1 (en) | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| GB201417803D0 (en) * | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
| BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| KR20190059874A (ko) * | 2016-04-08 | 2019-05-31 | 어댑티뮨 리미티드 | T 세포 수용체 |
| CN112912387A (zh) * | 2018-08-22 | 2021-06-04 | 弗雷德哈钦森癌症研究中心 | 靶向kras或her2抗原的免疫疗法 |
| EP3962939A4 (en) * | 2019-05-03 | 2023-05-17 | Gigamune, Inc. | MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM |
| JP7626780B2 (ja) | 2020-04-15 | 2025-02-04 | アムジエン・インコーポレーテツド | 遺伝子改変自己ｔ細胞を製造するためのプロセス |
-
2021
- 2021-12-21 AU AU2021410689A patent/AU2021410689A1/en active Pending
- 2021-12-21 EP EP21844879.3A patent/EP4267173A2/en active Pending
- 2021-12-21 MX MX2023007519A patent/MX2023007519A/es unknown
- 2021-12-21 CA CA3205810A patent/CA3205810A1/en active Pending
- 2021-12-21 WO PCT/US2021/064504 patent/WO2022140321A2/en not_active Ceased
- 2021-12-21 JP JP2023537297A patent/JP2024502235A/ja active Pending
- 2021-12-21 US US18/038,283 patent/US20240100162A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024502235A5 (enExample) | ||
| JP6612963B2 (ja) | 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法 | |
| CN108395479B (zh) | 一种有关kras基因突变的t细胞受体 | |
| Kannagi et al. | Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells | |
| JP2023106599A5 (enExample) | ||
| JP2021505136A5 (enExample) | ||
| Gambacorti-Passerini et al. | Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells | |
| KR20230079259A (ko) | Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도 | |
| CN110357953B (zh) | 识别人巨细胞病毒pp65抗原的TCR | |
| EP2504358B1 (en) | T cell receptors specific for immunodominant ctl epitopes of hcv | |
| JP2022538148A5 (enExample) | ||
| AU2022283277A9 (en) | T cell receptors targeting ras mutations and uses thereof | |
| JP2023534924A5 (enExample) | ||
| JP2022523024A5 (enExample) | ||
| CN114349847B (zh) | 靶向新型冠状病毒rna依赖性rna聚合酶的特异性tcr | |
| JP2025507939A (ja) | がんワクチンおよびその使用方法 | |
| JP7851611B2 (ja) | ループスを処置するための組成物及び方法 | |
| CA2660178C (en) | Promiscuous her-2/neu cd4 t cell epitopes | |
| JP2024523329A5 (enExample) | ||
| JP2023535366A5 (enExample) | ||
| Balog et al. | Nef: a pleiotropic modulator of primate lentivirus infectivity and pathogenesis | |
| JP2024534499A5 (enExample) | ||
| EP4328239A1 (en) | Immunotherapeutics based on magea1-derived epitopes | |
| WO2026040998A1 (zh) | Tp53突变体表位肽和特异性t细胞受体及其应用 | |
| CN118512580A (zh) | HBsAg特异性TCR-T细胞与PD-1抑制剂联合在制备治疗HBV感染相关疾病的药物中的用途 |